IGFBP3

Lumos Pharma Reports Third Quarter 2023 Financial Results and Clinical Development Updates

Retrieved on: 
Tuesday, November 7, 2023
Research, Transgender hormone therapy, American Association of Clinical Endocrinologists, Event, Child, LUMO, Pediatric endocrinology, Therapy, City of Hope National Medical Center, Rare, IGFBP3, Mother, MD, Quarter, SDS, Endocrine Society, Clinical trial, PEM, KOL, Lumos, University, Serum, University of Chile, Political moderate, European Society of Gynaecological Oncology, Growth hormone, Investment, Consistency, AHV, Silviculture, Pharmaceutical industry, Birth control, Endocrinology

AUSTIN, Texas, Nov. 07, 2023 (GLOBE NEWSWIRE) -- Lumos Pharma, Inc. (NASDAQ:LUMO), a clinical-stage biopharmaceutical company focused on therapeutics for rare diseases, today announced that topline results met primary and secondary endpoints for its Phase 2 Dose-Finding OraGrowtH210 Trial and Phase 2 Pharmacokinetic/Pharmacodynamic (PK/PD) OraGrowtH212 Trial evaluating oral LUM-201 for subjects with moderate pediatric growth hormone deficiency (PGHD) who screened PEM-positive utilizing Lumos Pharma’s predictive enrichment marker (PEM) strategy. Lumos also announced its financial results for the quarter ended September 30, 2023.

Key Points: 
  • Lumos also announced its financial results for the quarter ended September 30, 2023.
  • The Company expects cash use of approximately $9.0 to $10.0 million in the fourth quarter of 2023.
  • Net Loss – The net loss for the quarter ended September 30, 2023 was $8.3 million compared to a net loss of $7.3 million for the same period in 2022.
  • Lumos Pharma ended the third quarter 2023 with 7,914,582 shares outstanding.

Lumos Pharma Announces New Data and Analysis of 15 Subjects from OraGrowtH212 Trial Presented at the 2023 ESPE Annual Meeting

Retrieved on: 
Tuesday, September 26, 2023
IGFBP3, LUMO, Comparable, Time zone, Growth hormone, Serum, IGF, ESPE, Endocrine Society, Doctor of Philosophy, GH, Deconvolution, PEM, 2010 Formula Renault 3.5 Series, MD, Growth, Ageing, Patient, European Society for Paediatric Infectious Diseases, Poster, SD, AHV, Pharmaceutical industry, The Hague

“The presented results add to the growing body of evidence supporting the physiologic mechanism of action for LUM-201, as well as its potential as a treatment for moderate PGHD.

Key Points: 
  • “The presented results add to the growing body of evidence supporting the physiologic mechanism of action for LUM-201, as well as its potential as a treatment for moderate PGHD.
  • The slides presented at ESPE are available on the Posters & Publications page under the Investors & Media section of Lumos Pharma’s website.
  • At baseline, subjects (10M:5F) were (mean ± SD) aged 7.9±1.4 years, with IGF-1 SDS -0.82±0.9, and peak GH 7.2±2.2 ng/mL (clonidine stimulation), consistent with moderate PGHD.
  • Deconvolution analysis was performed on serum GH measured every 10 minutes (0800 h to 2000 h).

Enthera Pharmaceuticals Initiates Phase 1 Clinical Trial with Lead Candidate Ent001

Retrieved on: 
Tuesday, March 7, 2023
Science, Stem Cells, Biotechnology, Research, Pharmaceutical, Health, Diabetes, Clinical Trials, Pancreas, Cell death, Clinical trial, TMEM219, Inflammatory bowel disease, FIH, T1D, Mab, SAD, Patient, Pharmacokinetics, Apoptosis, Volunteering, IBD, IGFBP3, Inflammation, Safety, Medication, Pharmaceutical industry

Enthera Pharmaceuticals (“Enthera”), a biotech company developing first-in-class biologics for selected autoimmune conditions, today announces the start of a Phase 1 first-in-human (FIH) clinical trial with its lead candidate Ent001.

Key Points: 
  • Enthera Pharmaceuticals (“Enthera”), a biotech company developing first-in-class biologics for selected autoimmune conditions, today announces the start of a Phase 1 first-in-human (FIH) clinical trial with its lead candidate Ent001.
  • Ent001 is designed to bind to TMEM219 and prevent cell death and the inflammation underlying these disease states.
  • “The initiation of this trial is a major development milestone for Ent001 and transitions Enthera into a clinical stage company.
  • The Phase 1 trial will evaluate Ent001 in up to 30 healthy adult volunteers in a randomised, double-blind, placebo-controlled single ascending dose (SAD) study in the Netherlands.

METAvivor Announces Metastatic Breast Cancer Research Awards

Retrieved on: 
Monday, January 30, 2023
Linda, University of Texas Southwestern Medical Center, University, IGFBP3, Tamoxifen, Metastasis, Diagnosis, MBC, Support, Metabolism, Liver, Bachelor of Science, Treatment, Stanford University School of Medicine, Research, Brain, Memory, River, University of Maryland School of Medicine, Extracellular vesicle, Breast cancer, Patient, Quality of life, Social media, Presidential Early Career Award for Scientists and Engineers, Maryland School, Leclair, Doctor of Philosophy, Birth control, Pharmaceutical industry, Medical imaging, MD, Honours degree

Metastatic breast cancer (also known as stage IV or advanced stage cancer) is the spread of breast cancer to other parts of the body -- most commonly to the bones, liver, lungs and/or brain. Approximately 30% of early-stage breast cancer patients metastasize, with the mean survival after diagnosis being 33 months. In the U.S., only 2-5% of all cancer research funds are dedicated to metastatic breast cancer research – yet 98% of all breast cancer deaths are caused by a metastasis.

Key Points: 
  • METAvivor Research and Support announces 27 new grant awards for metastatic breast cancer research totaling $5.75 million.
  • METAvivor held its annual metastatic breast cancer research cycle in 2022 and as a result of strong support from generous donors, Metavivor is able to announce another banner year for peer-reviewed, metastatic breast cancer research funding.
  • ANNAPOLIS, Md., Jan. 30, 2023 /PRNewswire-PRWeb/ -- Metavivor Research and Support Inc., a non-profit organization dedicated to funding research for stage IV metastatic breast cancer (MBC), announces 27 grant awards totaling $5,750,000.
  • In the U.S., only 2-5% of all cancer research funds are dedicated to metastatic breast cancer research – yet 98% of all breast cancer deaths are caused by a metastasis.